1.MicroRNA-125b Accelerates and Promotes PML-RARa-driven Murine Acute Promyelocytic Leukemia.
Bo GUO ; Ran QIN ; Ji Jun CHEN ; Wen PAN ; Xue Chun LU
Biomedical and Environmental Sciences 2022;35(6):485-493
Objective:
Most acute promyelocytic leukemia cases are characterized by the PML-RARa fusion oncogene and low white cell counts in peripheral blood.
Methods:
Based on the frequent overexpression of miR-125-family miRNAs in acute promyelocytic leukemia, we examined the consequence of this phenomenon by using an inducible mouse model overexpressing human miR-125b.
Results:
MiR-125b expression significantly accelerates PML-RARa-induced leukemogenesis, with the resultant induced leukemia being partially dependent on continued miR-125b overexpression. Interestingly, miR-125b expression led to low peripheral white cell counts to bone marrow blast percentage ratio, confirming the clinical observation in acute promyelocytic leukemia patients.
Conclusion
This study suggests that dysregulated miR-125b expression is actively involved in disease progression and pathophysiology of acute promyelocytic leukemia, indicating that targeting miR-125b may represent a new therapeutic option for acute promyelocytic leukemia.
Animals
;
Humans
;
Leukemia, Promyelocytic, Acute/metabolism*
;
Mice
;
MicroRNAs/genetics*
;
Oncogene Proteins, Fusion/therapeutic use*
2.Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer.
Journal of Southern Medical University 2015;35(5):753-757
OBJEVTIVETo evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer (NSCLC) with or without EML4-ALK rearrangement.
METHODSTwenty-one ALK-positive and 50 ALK-negative NSCLC patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study. The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival (PFS), and treatment-related adverse events were analyzed.
RESULTSCrizotinib treatment obviously prolonged the PFS in EML4-ALK-positive patients with an objective response rate (OOR) of 61.9% and a median response duration of 16 months, which were significantly better than those in with ALK-negative patients and patients without ALK testing who received different second-line therapies.
CONCLUSIONCrizotinib is superior to platinum-based chemotherapy in NSCLC patients with ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.
Carcinoma, Non-Small-Cell Lung ; drug therapy ; Disease-Free Survival ; Humans ; Lung Neoplasms ; drug therapy ; Oncogene Proteins, Fusion ; Pyrazoles ; administration & dosage ; therapeutic use ; Pyridines ; administration & dosage ; therapeutic use
3.Study of EML4-ALK fusion gene as a biomarker in non-small cell lung cancer.
Lu WANG ; Yao-hui WANG ; Chun-yang LIU ; Mei HAN ; Shu-peng ZHANG ; Ren-sheng LAI
Chinese Journal of Pathology 2011;40(11):788-790
Biomarkers, Tumor
;
metabolism
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
metabolism
;
pathology
;
Humans
;
Lung Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
Oncogene Proteins, Fusion
;
chemistry
;
metabolism
;
Protein Kinase Inhibitors
;
therapeutic use
;
Pyrazoles
;
therapeutic use
;
Pyridines
;
therapeutic use
;
Pyrimidines
;
therapeutic use
;
Smoking
4.Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.
Shumin CHEN ; Ye LI ; Zheng WANG ; Lin FENG ; Yueping JIA ; Xiaodong MO ; Yu WANG ; Qian JIANG ; Xiaojun HUANG ; Yueyun LAI
Chinese Medical Journal 2023;136(11):1382-1384
5.Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial.
Sai-Juan CHEN ; Li-Juan CHEN ; Guang-Biao ZHOU
Journal of Experimental Hematology 2005;13(1):1-8
In the last twenty years, using all-trans retinoic acid (ATRA) as a differentiation inducer, Shanghai Institute of Hematology has achieved an important breakthrough in the treatment of acute promyelocytic leukemia (APL), which realized the theory of reversing phenotype of cells and provided a successful model of differentiation therapy in cancers. Our group first discovered in the world the variant chromosome translocation t(11;17)(q23;q21) of APL, and cloned the PML-RAR alpha, PLZF-RAR alpha and NPM-RAR alpha fusion genes corresponding to the characterized chromosome translocations t(15;17); t(11;17) and t(5;17) in APL. Moreover, establishment of transgenic mice model of APL proved their effects on leukemogenesis. The ability of ATRA to modify the recruitment of nuclear receptor co-repressor with PML-RAR alpha but not PLZF-RAR alpha caused by the variant chromosome translocation elucidated the therapeutic mechanism of ATRA from the molecular level and provides new insight into transcription-modulating therapy. Since 1994, our group has successfully applied arsenic trioxide (As(2)O(3)) in treating relapsed APL patients, with the complete remission rate of 70% - 80%. The molecular mechanism study revealed that As(2)O(3) exerts a dose-dependent dual effect on APL. Low-dose As(2)O(3) induced partial differentiation of APL cells, while the higher dose induced apoptosis. As(2)O(3) binds ubiquitin like SUMO-1 through the lysine 160 of PML, resulting in the degradation of PML-RAR alpha. Taken together, ATRA and As(2)O(3) target the transcription factor PML-RAR alpha, the former by retinoic acid receptor and the latter by PML sumolization, both induce PML-RAR alpha degradation and APL cells differentiation and apoptosis. Because of the different acting pathways, ATRA and As(2)O(3) have no cross-resistance and can be used as combination therapy. Clinical trial in newly diagnosed APL patients showed that ATRA/As(2)O(3) in combination yields a longer disease-free survival time. With the median survival of 18 months, none of the 20 cases in combination treatment relapsed, whereas 7 relapsed in 37 cases in mono-treatment. This is the best clinical effect achieved in treating adult acute leukemia to this day, possibly making APL the first adult curable leukemia. Based on the great success of the pathogenetic gene target therapy in APL, this strategy may extend to other leukemias. Combination of Gleevec and arsenic agents in treating chronic myeloid leukemia has already make a figure both in clinical and laboratory research, aiming at counteracting the abnormal tyrosine kinase activity of ABL and the degradating BCR-ABL fusion protein. In acute myeloid leukemia M(2b), using new target therapy degradating AML1-ETO fusion protein and reducing the abnormal tyrosine kinase activity of c-kit will also lead to new therapeutic management in acute leukemias.
Antineoplastic Agents
;
therapeutic use
;
Benzamides
;
Fusion Proteins, bcr-abl
;
genetics
;
metabolism
;
Humans
;
Imatinib Mesylate
;
Leukemia, Promyelocytic, Acute
;
drug therapy
;
genetics
;
metabolism
;
Oncogene Proteins, Fusion
;
genetics
;
metabolism
;
Piperazines
;
therapeutic use
;
Protein-Tyrosine Kinases
;
antagonists & inhibitors
;
metabolism
;
Pyrimidines
;
therapeutic use
;
Receptors, Retinoic Acid
;
genetics
;
metabolism
;
Tretinoin
;
therapeutic use
6.Role of autophagy in acute myeloid leukemia therapy.
Su-Ping ZHANG ; Yu-Na NIU ; Na YUAN ; Ai-Hong ZHANG ; Dan CHAO ; Qiu-Ping XU ; Li-Jun WANG ; Xue-Guang ZHANG ; Wen-Li ZHAO ; Yun ZHAO ; Jian-Rong WANG
Chinese Journal of Cancer 2013;32(3):130-135
Despite its dual role in determining cell fate in a wide array of solid cancer cell lines, autophagy has been robustly shown to suppress or kill acute myeloid leukemia cells via degradation of the oncogenic fusion protein that drives leukemogenesis. However, autophagy also induces the demise of acute leukemia cells that do not express the known fusion protein, though the molecular mechanism remains elusive. Nevertheless, since it can induce cooperation with apoptosis and differentiation in response to autophagic signals, autophagy can be manipulated for a better therapy on acute myeloid leukemia.
Antineoplastic Agents
;
therapeutic use
;
Apoptosis
;
Apoptosis Regulatory Proteins
;
metabolism
;
Autophagy
;
drug effects
;
Humans
;
Leukemia, Myeloid, Acute
;
drug therapy
;
metabolism
;
pathology
;
Leukemia, Promyelocytic, Acute
;
drug therapy
;
metabolism
;
pathology
;
Molecular Targeted Therapy
;
Oncogene Proteins, Fusion
;
metabolism
;
Tretinoin
;
therapeutic use
7.A Case of B-cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma in a Korean Child.
Jeong Yeal AHN ; Yiel Hea SEO ; Pil Whan PARK ; Kyung Hee KIM ; Mi Jung PARK ; Ji Hoon JEONG ; Soon Ho PARK ; Young Hee SONG
Annals of Laboratory Medicine 2012;32(2):162-166
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (intermediate DLBCL/BL), is a heterogeneous group with some features resembling DLBCL and others resembling BL. Here, we report a case of intermediate DLBCL/BL in a Korean child. A 2-yr-old male was admitted for evaluation and management of left hip pain. Immunohistochemistry of a biopsy of the femur neck revealed tumor cells positive for CD20, CD10, BCL2, BCL6, and Ki67. A bone marrow (BM) aspirate smear revealed that 49.3% of all nucleated cells were abnormal lymphoid cells, composed of large- and medium-sized cells. Immunophenotyping of the neoplastic cells revealed positivity for CD19, CD10, CD20, and sIg lambda and negativity for CD34, Tdt, and myeloperoxidase (MPO). Cytogenetic and FISH analyses showed a complex karyotype, including t(8;14)(q24.1;q32) and IGH-MYC fusion. Intensive chemotherapy was initiated, including prednisone, vincristine, L-asparaginase, daunorubicin, and central nervous system prophylaxis with intrathecal methotrexate (MTX) and cytarabine. One month after the initial diagnosis, BM examination revealed the persistent of abnormal lymphoid cells; cerebrospinal fluid cytology, including cytospin, showed atypical lymphoid cells. The patient was treated again with cyclophosphamide, vincristine, prednisone, adriamycin, MTX, and intrathecal MTX and cytarabine. The patient died of sepsis 5 months after the second round of chemotherapy.
Antineoplastic Agents/therapeutic use
;
Bone Marrow Cells/pathology
;
Child, Preschool
;
Chromosomes, Human, Pair 14
;
Chromosomes, Human, Pair 8
;
Cyclophosphamide/therapeutic use
;
Doxorubicin/therapeutic use
;
Drug Therapy, Combination
;
Femur Neck/pathology
;
Humans
;
Immunohistochemistry
;
Immunophenotyping
;
In Situ Hybridization, Fluorescence
;
Karyotyping
;
Lymphoma, B-Cell/*diagnosis/drug therapy
;
Male
;
Methotrexate/therapeutic use
;
Oncogene Proteins, Fusion/genetics
;
Prednisolone/therapeutic use
;
Republic of Korea
;
Translocation, Genetic
;
Treatment Outcome
;
Vincristine/therapeutic use
8.Optimized expression, preparation of human papillomavirus 16 L2E7 fusion protein and its inhibitory effect on tumor growth in mice.
Yunshui JIANG ; Jianbo LI ; Meng GAO ; Jiao REN ; Sufeng JIN ; Gang CHEN ; Jie WU ; Fangcheng ZHUANG ; Houwen TIAN
Chinese Journal of Biotechnology 2015;31(4):566-576
HPV16 L2E7 is a fusion protein used for therapeutical vaccine targeting HPV virus. To increase its expression in Escherichia coli, we optimized the codon usage of HPV16 l2e7 gene based on its codon usage bias. The optimized gene of HPV16 sl2e7 was cloned into three different vectors: pGEX-5X-1, pQE30, ET41a, and expressed in JM109, JM109 (DE3) and BL21 (DE3) lines separately. A high expression line was selected with pET41a vector in BL21 (DE3) cells. After optimization of the growth condition, including inoculation amount, IPTG concentration, induction time and temperature, the expression level of HPV16 L2E7 was increased from less than 10% to about 28% of total protein. HPV16 L2E7 protein was then purified from 15 L culture by means of SP Sepharose Fast Flow, Q Sepharose Fast Flow and Superdex 200 pg. After renaturing, HPV16 L2E7 protein with ≥ 95% purity was achieved, which was confirmed via SDS-PAGE gel and Western blotting. The combined use of purified HPV16 L2E7 and CpG helper has shown clear inhibition of tumor growth in mice injected with tumor cells, with six out of eight mice shown no sign of tumor. This study lays a solid foundation for a new pipeline of large-scale vaccine production.
Animals
;
Capsid Proteins
;
biosynthesis
;
Codon
;
Electrophoresis, Polyacrylamide Gel
;
Escherichia coli
;
Genetic Vectors
;
Human papillomavirus 16
;
Mice
;
Neoplasms, Experimental
;
prevention & control
;
Oncogene Proteins, Viral
;
biosynthesis
;
Papillomavirus E7 Proteins
;
biosynthesis
;
Papillomavirus Vaccines
;
therapeutic use
;
Recombinant Fusion Proteins
;
biosynthesis
9.A Case of Therapy-Related Acute Myeloid Leukemia With a Normal Karyotype After Sustained Molecular Complete Remission of Acute Promyelocytic Leukemia.
Sang Hyuk PARK ; Hyun Sook CHI ; Young Uk CHO ; Seongsoo JANG ; Chan Jeoung PARK ; Je Hwan LEE
Annals of Laboratory Medicine 2014;34(1):68-70
No abstract available.
Antineoplastic Agents/*adverse effects/*therapeutic use
;
Bone Marrow Cells/metabolism
;
Humans
;
Karyotyping
;
Leukemia, Myeloid, Acute/*chemically induced/*diagnosis/genetics
;
Leukemia, Promyelocytic, Acute/*drug therapy
;
Male
;
Middle Aged
;
Oncogene Proteins, Fusion/genetics
;
Remission Induction
;
Tretinoin/therapeutic use
10.Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide.
Rui HAO ; Lide SU ; Yiming SHAO ; Na BU ; Liya MA ; Hua NARANMANDURA
Journal of Zhejiang University. Medical sciences 2018;47(5):541-551
Promyelocytic leukemia (PML) protein, a tumor suppressor, plays an important role in patients with acute promyelocytic leukemia (APL) receiving arsenic trioxide (AsO) therapy. APL is a M3 subtype of acute myeloid leukemia (AML), which is characterized by expression of PML-RARα (P/R) fusion protein, leading to the oncogenesis. AsO is currently used as the first-line drug for patients with APL, and the mechanism may be:AsO directly binds to PML part of P/R protein and induces multimerization of related proteins, which further recruits different functional proteins to reform PML nuclear bodies (PML-NBs), and finally it degraded by SUMOylation and ubiquitination proteasomal pathway. Gene mutations may lead to relapse and drug resistance after AsO treatment. In this review, we discuss the structure and function of PML proteins; the pathogenesis of APL induced by P/R fusion protein; the involvement of PML protein in treatment of APL patient with AsO; and explain how PML protein mutations could cause resistance to AsO therapy.
Antineoplastic Agents
;
therapeutic use
;
Arsenic Trioxide
;
therapeutic use
;
Drug Resistance, Neoplasm
;
genetics
;
Humans
;
Leukemia, Promyelocytic, Acute
;
drug therapy
;
Mutation
;
Oncogene Proteins, Fusion
;
metabolism
;
Promyelocytic Leukemia Protein
;
chemistry
;
genetics
;
metabolism